Analysts Offer Predictions for JSPR FY2025 Earnings

Jasper Therapeutics, Inc. (NASDAQ:JSPR) – Equities researchers at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of Jasper Therapeutics in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst P. Stavropoulos anticipates that the company will post earnings of ($4.24) per share for the year. The consensus estimate for Jasper Therapeutics’ current full-year earnings is ($4.47) per share.

Jasper Therapeutics (NASDAQ:JSPR) last released its quarterly earnings results on Thursday, November 7th. The company reported ($1.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.09) by ($0.15).

Several other research firms have also recently issued reports on JSPR. BMO Capital Markets began coverage on shares of Jasper Therapeutics in a research note on Friday, December 6th. They set an “outperform” rating and a $63.00 price target on the stock. Royal Bank of Canada decreased their target price on shares of Jasper Therapeutics from $68.00 to $48.00 and set an “outperform” rating on the stock in a research report on Thursday, January 9th. JMP Securities reiterated a “market outperform” rating and issued a $70.00 price target on shares of Jasper Therapeutics in a report on Monday, January 6th. Finally, HC Wainwright reduced their price target on Jasper Therapeutics from $60.00 to $40.00 and set a “buy” rating on the stock in a research note on Friday, January 10th. Ten analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $67.75.

Jasper Therapeutics Trading Up 3.4 %

Jasper Therapeutics stock opened at $5.70 on Wednesday. The stock has a 50-day moving average price of $18.62 and a 200 day moving average price of $19.34. Jasper Therapeutics has a 52 week low of $5.25 and a 52 week high of $31.01. The stock has a market cap of $85.50 million, a PE ratio of -1.20 and a beta of 2.18.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in JSPR. JPMorgan Chase & Co. increased its stake in Jasper Therapeutics by 239.8% during the third quarter. JPMorgan Chase & Co. now owns 16,391 shares of the company’s stock worth $308,000 after acquiring an additional 11,567 shares during the last quarter. Barclays PLC increased its position in Jasper Therapeutics by 320.7% during the 3rd quarter. Barclays PLC now owns 16,146 shares of the company’s stock worth $304,000 after purchasing an additional 12,308 shares in the last quarter. Jane Street Group LLC purchased a new position in Jasper Therapeutics in the third quarter valued at approximately $251,000. Wellington Management Group LLP acquired a new position in Jasper Therapeutics during the third quarter valued at approximately $447,000. Finally, State Street Corp lifted its position in Jasper Therapeutics by 12.3% during the third quarter. State Street Corp now owns 214,883 shares of the company’s stock valued at $4,042,000 after buying an additional 23,564 shares in the last quarter. 79.85% of the stock is owned by hedge funds and other institutional investors.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.